IK Investment Partners (“IK”) is pleased to announce that the IK VII Fund (“the Fund”) has entered into exclusive negotiations with Dentressangle regarding the sale of Marle International SAS (“Marle” or “the Company”), a leading European manufacturer of orthopaedic implants. The transaction remains subject to the information and consultation process of the relevant employee representative bodies in accordance with applicable laws and to the approval of the competent antitrust authorities.
Founded in 1964, Marle has grown to become a leading manufacturer of hip and knee implants and instruments for the orthopaedic industry. Covering the full value chain, including prototyping, forging, casting and finishing, Marle acts as a strategic partner to medical technology companies worldwide, producing 1.5 million implants annually. The Company operates six production sites in France and Switzerland and employs c. 750 FTEs.
Rémi Buttiaux, Partner at IK Investment Partners and advisor to the IK VII Fund, says: “Under the leadership of Antonio Gil and IK’s active ownership, Marle has completed a strategic acquisition in Switzerland and has grown substantially in North America and Asia. The Company has also further strengthened its array of capabilities and services in line with its long-term commitment to be the partner of choice for its clients.”
Antonio Gil, President at Marle, says: “I would like to thank IK for their active support over the last three years which has enabled Marle to reinforce its capabilities. We are enthusiastic about Marle’s long-term growth potential and are convinced that Dentressangle is the right partner to accompany us in the next phase of our development.”
Thierry Coloigner, Managing Partner at Dentressangle Mid & Large Cap, says: “We are privileged to partner with Marle. The company has an exciting future ahead of it and we look forward to supporting the management team in realising its long-term ambition for the Company by offering increasingly higher value-added services to its clients and pursuing targeted acquisitions.”
Parties involved on the transaction
Buyside
DENTRESSANGLE: Thierry Coloigner, Olivier Verdet, Charles Wacheux Camille Dussaix
M&A Advisors: Messier Maris (Erik Maris, Driss Mernissi, Laura Scolan), Wil Consulting (Jacques Ittah)
Legal Advisor: Bredin Prat (Olivier Assant, Adrien Simon, Karine Sultan)
Strategic Due Diligence: Bain & Company (Jean-Marc Leroux, David Gautard)
Financial Due Diligence: Eight Advisory (Stéphane Vanbergue, Christophe Puissegur)
Tax Due Diligence: Eight Advisory Avocats (Guillaume Rembry, Baptiste Gachet)
Legal Due Diligence: Simmons & Simmons (Guillaume Denis-Faure, Simonetta Giordano)
Financing: Capza (Laurent Bénard, Guillaume de Jongh, Oriane Mizrahi, Sabine Barral)
Sellside
IK Investment Partners: Rémi Buttiaux, Dan Soudry, Vincent Elriz, Guillaume Veber
Carlyle Europe Technology Partners: Vladimir Lasocki, Charles Villet
M&A Advisor: Natixis Partners (Francois Rivalland, Julien Plantive)
Legal Advisors: DLA Piper (Xavier Norlain, Aymeric Robine), Willkie Farr Gallagher (Eduardo Fernandez)
Strategic Due Diligence: BCG (Benjamin Entraygues, Florian Kahn, Chloé Caparros)
For further questions, please contact:
IK Investment Partners
Rémi Buttiaux, Partner
Phone: +33 1 44 43 06 60
Mikaela Murekian, Director Communications & ESG
Phone: +44 77 87 573 566
mikaela.murekian@ikinvest.com
Marle and DENTRESSANGLE
DGM
Thomas Roborel de Climens: thomasdeclimens@dgm-conseil.fr
About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised close to €10 billion of capital and invested in over 125 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com
About Marle
Marle has a 40-year track record serving the orthopaedic implant industry and specialises in the precision forging, machining and finishing of hip, knee, shoulder, spine and extremities implants as well as instruments. It has acquired and developed a wide span of technologies dedicated to the medical industry and now offers one of the most comprehensive ranges of manufacturing services in the orthopaedics market. For more information, visit www.marle.fr
